Are mounjaro and zepbound the same?
Zepbound vs Mounjaro
Zepbound and Mounjaro both contain tirzepatide, a once‑weekly injectable GIP/GLP‑1 receptor agonist made by Eli Lilly. The only distinction is their FDA approval:
Shop Medications
- Zepbound is approved for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) plus one weight‑related condition.
- Mounjaro is approved for improving blood sugar control in adults with type 2 diabetes.
Why two brands?
Mounjaro has been used off‑label for weight loss. Following the Ozempic→Wegovy model, Zepbound was introduced after the SURMOUNT‑1 trial showed > 20% average weight loss over 72 weeks at the highest dose.
How they work
Tirzepatide mimics GLP‑1 and GIP hormones to:
- Slow gastric emptying and reduce appetite
- Increase insulin release and lower blood sugar
Shared side effects
- Gastrointestinal: nausea, diarrhea, vomiting, indigestion, constipation
- Other: decreased appetite, burping, fatigue, stomach pain, hair loss, injection site reactions, dizziness
Serious risks (seek immediate care):
Why Pay Full Price?
Search our full medication catalogue and save up to 80% - no insurance needed.
See Prices Now- Allergic reactions (hives, throat/tongue swelling, breathing difficulty)
- Pancreatitis (severe abdominal pain)
- Kidney injury (dehydration symptoms)
- Gallbladder issues (upper abdominal pain, fever)
- Hypoglycemia when combined with insulin or sulfonylureas
- Diabetic retinopathy worsening
- Thyroid tumors (lump in neck)
- Suicidal thoughts or depression
Boxed warning
- Avoid if personal/family history of medullary thyroid carcinoma or MEN 2 syndrome
Key differences
- Indication: Zepbound for weight loss; Mounjaro for type 2 diabetes
- Dosing: Both start at 2.5 mg weekly, titrated up to 15 mg
- Cost & savings: Similar list price (~$1,300/month); Lilly offers assistance programs
Switching brands
Because the active ingredient and dosing pens are identical, you may maintain your current dose when switching. Always consult your provider for guidance.
Sources
- Medscape: tirzepatide overview. Accessed 2025.
- DailyMed: Zepbound & Mounjaro prescribing information. Accessed 2025.
- Forbes: tirzepatide and blood pressure study. Accessed 2024.
